Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21^Waf1/Cip1

REFERENCES

• Anderson, M. E., B. Woelker, M. Reed, P. Wang, and P. Tegtmeyer. 1997. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. Mol. Cell. Biol. 17:6255–6264.
   PubMed Web of Science ®Google Scholar
• Appella, E., and C. W. Anderson. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764–2772.
   PubMedGoogle Scholar
• Barlev, N. A., L. Liu, N. H. Chehab, K. Mansfield, K. G. Harris, T. D. Halazonetis, and S. L. Berger. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8:1243–1254.
   PubMed Web of Science ®Google Scholar
• Blagosklonny, M. V., R. Robey, D. L. Sackett, L. Du, F. Traganos, Z. Darzynkiewicz, T. Fojo, and S. E. Bates. 2002. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. 1:937–941.
   PubMed Web of Science ®Google Scholar
• Bode, A. M., and Z. Dong. 2004. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4:793–805.
   PubMed Web of Science ®Google Scholar
• Brooks, C. L., and W. Gu. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15:164–171.
   PubMed Web of Science ®Google Scholar
• Bruins, W., E. Zwart, L. D. Attardi, T. Iwakuma, E. M. Hoogervorst, R. B. Beems, B. Miranda, C. T. van Oostrom, J. van den Berg, G. J. van den Aardweg, G. Lozano, H. van Steeg, T. Jacks, and A. de Vries. 2004. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol. Cell. Biol. 24:8884–8894.
   PubMed Web of Science ®Google Scholar
• Chan, H. M., M. Krstic-Demonacos, L. Smith, C. Demonacos, and N. B. La Thangue. 2001. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3:667–674.
   PubMed Web of Science ®Google Scholar
• Chen, D., N. Kon, M. Li, W. Zhang, J. Qin, and W. Gu. 2005. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121:1071–1083.
   PubMed Web of Science ®Google Scholar
• Cheng, H. L., R. Mostoslavsky, S. Saito, J. P. Manis, Y. Gu, P. Patel, R. Bronson, E. Appella, F. W. Alt, and K. F. Chua. 2003. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA 100:10794–10799.
   PubMed Web of Science ®Google Scholar
• Dornan, D., M. Ecker, M. Wallace, H. Shimizu, E. Ramsay, T. R. Hupp, and K. L. Ball. 2004. Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol. Cell. Biol. 24:10083–10098.
   PubMedGoogle Scholar
• Dornan, D., and T. R. Hupp. 2001. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep. 2:139–144.
   PubMedGoogle Scholar
• Dornan, D., H. Shimizu, L. Burch, A. J. Smith, and T. R. Hupp. 2003. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell. Biol. 23:8846–8861.
   PubMedGoogle Scholar
• Dornan, D., H. Shimizu, N. D. Perkins, and T. R. Hupp. 2003. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 278:13431–13441.
   PubMedGoogle Scholar
• Dornan, D., I. Wertz, H. Shimizu, D. Arnott, G. D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, and V. M. Dixit. 2004. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429:86–92.
   PubMed Web of Science ®Google Scholar
• Dumaz, N., and D. W. Meek. 1999. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18:7002–7010.
   PubMed Web of Science ®Google Scholar
• Espinosa, J. M., and B. M. Emerson. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8:57–69.
   PubMed Web of Science ®Google Scholar
• Feng, L., T. Lin, H. Uranishi, W. Gu, and Y. Xu. 2005. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25:5389–5395.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., L. Wu, and A. J. Levine. 1999. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55:96–107.
   PubMed Web of Science ®Google Scholar
• Gartel, A. L., and S. Radhakrishnan. 2005. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65:3980–3985.
   PubMed Web of Science ®Google Scholar
• Gartel, A. L., and A. L. Tyner. 1999. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp. Cell Res. 246:280–289.
   PubMed Web of Science ®Google Scholar
• Giaccia, A. J., and M. Kastan. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:2973–2983.
   PubMed Web of Science ®Google Scholar
• Gottifredi, V., and C. Prives. 2001. Molecular biology. Getting p53 out of the nucleus. Science 292:1851–1852.
   PubMedGoogle Scholar
• Gottifredi, V., S. Shieh, Y. Taya, and C. Prives. 2001. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc. Natl. Acad. Sci. USA 98:1036–1041.
   PubMed Web of Science ®Google Scholar
• Gu, W., and R. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606.
   PubMed Web of Science ®Google Scholar
• Guo, A., P. Salomoni, J. Luo, A. Shih, S. Zhong, W. Gu, and P. P. Pandolfi. 2000. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2:730–736.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
   PubMed Web of Science ®Google Scholar
• Ho, J. S., W. Ma, D. Y. Mao, and S. Benchimol. 2005. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell. Biol. 25:7423–7431.
   PubMed Web of Science ®Google Scholar
• Hofmann, T. G., A. Moller, H. Sirma, H. Zentgraf, Y. Taya, W. Droge, H. Will, and M. L. Schmitz. 2002. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4:1–10.
   PubMed Web of Science ®Google Scholar
• Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27.
   PubMed Web of Science ®Google Scholar
• Hupp, T. R., and D. P. Lane. 1994. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:865–875.
   PubMedGoogle Scholar
• Hupp, T. R., A. Sparks, and D. P. Lane. 1995. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237–245.
   PubMed Web of Science ®Google Scholar
• Ito, A., Y. Kawaguchi, C. H. Lai, J. J. Kovacs, Y. Higashimoto, E. Appella, and T. P. Yao. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21:6236–6245.
   PubMed Web of Science ®Google Scholar
• Ito, A., C. H. Lai, X. Zhao, S. Saito, M. H. Hamilton, E. Appella, and T. P. Yao. 2001. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20:1331–1340.
   PubMed Web of Science ®Google Scholar
• Jayaraman, J., and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021–1029.
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W. 2002. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1:287–299.
   PubMed Web of Science ®Google Scholar
• Ju, R., and M. Muller. 2003. Histone deacetylase inhibitors activate p21WAF1 expression via ATM. Cancer Res. 63:2891–2897.
   PubMed Web of Science ®Google Scholar
• Juan, L. J., W. J. Shia, M. H. Chen, W. M. Yang, E. Seto, Y. S. Lin, and C. W. Wu. 2000. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275:20436–20443.
   PubMed Web of Science ®Google Scholar
• Kaeser, M. D., and R. D. Iggo. 2002. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99:95–100.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–1072.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299–303.
   PubMed Web of Science ®Google Scholar
• Lagger, G., A. Doetzlhofer, B. Schuettengruber, E. Haidweger, E. Simboeck, J. Tischler, S. Chiocca, G. Suske, H. Rotheneder, E. Wintersberger, and C. Seiser. 2003. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell. Biol. 23:2669–2679.
   PubMed Web of Science ®Google Scholar
• Lambert, P. F., F. Kashanchi, M. F. Radonovich, R. Shiekhattar, and J. N. Brady. 1998. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273:33048–33053.
   PubMed Web of Science ®Google Scholar
• Leng, R. P., Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G. Lozano, R. Hakem, and S. Benchimol. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779–791.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Li, H., and X. Wu. 2004. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem. Biophys. Res. Commun. 324:860–867.
   PubMedGoogle Scholar
• Li, M., J. Luo, C. L. Brooks, and W. Gu. 2002. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277:50607–50611.
   PubMed Web of Science ®Google Scholar
• Lill, N. L., S. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823–827.
   PubMed Web of Science ®Google Scholar
• Liu, L., D. Scolnick, R. C. Trievel, H. B. Zhang, R. Marmorstein, T. D. Halazonetis, and S. L. Berger. 1999. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19:1202–1209.
   PubMed Web of Science ®Google Scholar
• Luo, J., M. Li, Y. Tang, M. Laszkowska, R. G. Roeder, and W. Gu. 2004. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 101:2259–2264.
   PubMed Web of Science ®Google Scholar
• Luo, J., A. Y. Nikolaev, S. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, and W. Gu. 2001. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107:137–148.
   PubMed Web of Science ®Google Scholar
• Luo, J., F. Su, D. Chen, A. Shiloh, and W. Gu. 2000. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377–381.
   PubMed Web of Science ®Google Scholar
• MacPherson, D., J. Kim, T. Kim, B. K. Rhee, C. T. Van Oostrom, R. A. DiTullio, M. Venere, T. D. Halazonetis, R. Bronson, A. De Vries, M. Fleming, and T. Jacks. 2004. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 23:3689–3699.
   PubMed Web of Science ®Google Scholar
• Marks, P. A., V. M. Richon, R. Breslow, and R. A. Rifkind. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13:477–483.
   PubMed Web of Science ®Google Scholar
• Marks, P. A., V. M. Richon, and R. A. Rifkind. 2000. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:1210–1216.
   PubMed Web of Science ®Google Scholar
• McKinney, K., M. Mattia, V. Gottifredi, and C. Prives. 2004. p53 linear diffusion along DNA requires its C terminus. Mol. Cell 16:413–424.
   PubMedGoogle Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Mujtaba, S., Y. He, L. Zeng, S. Yan, O. Plotnikova, Sachchidanand, R. Sanchez, N. J. Zeleznik-Le, Z. Ronai, and M. M. Zhou. 2004. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell 13:251–263.
   PubMed Web of Science ®Google Scholar
• Nakajima, H., Y. B. Kim, H. Terano, M. Yoshida, and S. Horinouchi. 1998. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241:126–133.
   PubMed Web of Science ®Google Scholar
• Nakano, K., T. Mizi, Y. Sowa, T. Orita, T. Yoshino, Y. Okuyama, T. Fujita, N. Ohtani-Fujita, Y. Matsukawa, T. Tokino, H. Yamagishi, T. Oka, H. Nomura, and T. Sakai, T. 1997. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem. 272:22199–22206.
   PubMed Web of Science ®Google Scholar
• Nie, Y., H. H. Li, C. M. Bula, and X. Liu. 2000. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. Mol. Cell. Biol. 20:741–748.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83.
   PubMed Web of Science ®Google Scholar
• Ou, Y. H., P. H. Chung, T. P. Sun, and S. Y. Shieh. 2005. p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol. Biol. Cell 16:1684–1695.
   PubMedGoogle Scholar
• Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112–126.
   PubMed Web of Science ®Google Scholar
• Rajgolikar, G., K. K. Chan, and H. C. Wang. 1998. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. 51:29–38.
   PubMed Web of Science ®Google Scholar
• Sakaguchi, K., J. E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C. W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841.
   PubMed Web of Science ®Google Scholar
• Shieh, S. Y., J. Ahn, K. Tamai, Y. Taya, and C. Prives. 2000. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:289–300.
   PubMed Web of Science ®Google Scholar
• Takenaka, I., F. F. Morin, B. R. Seizinger, and N. Kley. 1995. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem. 270:5405–5411.
   PubMed Web of Science ®Google Scholar
• Vaziri, H., S. K. Dessain, E. Ng Eaton, S. I. Imai, R. A. Frye, T. K. Pandita, L. Guarente, and R. A. Weinberg. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149–159.
   PubMed Web of Science ®Google Scholar
• Wang, Y., and C. Prives. 1995. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376:88–91.
   PubMed Web of Science ®Google Scholar
• Yu, X., Z. S. Guo, M. G. Marcu, L. Neckers, D. M. Nguyen, G. A. Chen, and D. S. Schrump. 2002. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94:504–513.
   PubMed Web of Science ®Google Scholar
• Zhu, W. G., T. Hileman, Y. Ke, P. Wang, S. Lu, W. Duan, Z. Dai, T. Tong, M. A. Villalona-Calero, C. Plass, and G. A. Otterson. 2004. 5-Aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J. Biol. Chem. 279:15161–15166.
   PubMed Web of Science ®Google Scholar
• Zhu, W. G., R. R. Lakshmanan, M. D. Beal, and G. A. Otterson. 2001. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61:1327–1333.
   PubMed Web of Science ®Google Scholar
• Zhu, W. G., and G. A. Otterson. 2003. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Cancer Agents 3:187–199.
   PubMedGoogle Scholar
• Zhu, W. G., K. Srinivasan, Z. Dai, W. Duan, L. J. Druhan, H. Ding, L. Yee, M. A. Villalona-Calero, C. Plass, and G. A. Otterson. 2003. Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21Cip1 promoter. Mol. Cell Biol. 23:4056–4065.
   PubMed Web of Science ®Google Scholar